BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32951452)

  • 41. Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer.
    Bogart JA; Waqar SN; Mix MD
    J Clin Oncol; 2022 Feb; 40(6):661-670. PubMed ID: 34985935
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Watkins JM; Wahlquist AE; Shirai K; Garrett-Mayer E; Aguero EG; Fortney JA; Sherman CA; Sharma AK
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1108-13. PubMed ID: 19084345
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Prognostic evaluation of nutritional indicators in patients with limited-stage small cell lung cancer].
    Zhang JQ; Wang YY; Xu KP; Qi J; Wang X; Xu LM; Liu NN; Zhao LJ; Wang P
    Zhonghua Zhong Liu Za Zhi; 2019 Dec; 41(12):937-942. PubMed ID: 31874552
    [No Abstract]   [Full Text] [Related]  

  • 44. Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC.
    Welsh JW; Heymach JV; Guo C; Menon H; Klein K; Cushman TR; Verma V; Hess KR; Shroff G; Tang C; Skoulidis F; Jeter M; Comeaux N; Patel RR; Chen D; Ozgen T; Nguyen QN; Chang JY; Altan M; Zhang J; Papadimitrakopoulou VA; Simon GR; Byers LA; Glisson B
    J Thorac Oncol; 2020 Dec; 15(12):1919-1927. PubMed ID: 32916308
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans.
    Azar I; Yazdanpanah O; Jang H; Austin A; Kim S; Chi J; Alkassis S; Saha BK; Chopra A; Neu K; Mehdi S; Mamdani H
    JAMA Netw Open; 2022 Oct; 5(10):e2237699. PubMed ID: 36264573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement.
    Valan CD; Slagsvold JE; Halvorsen TO; Herje M; Bremnes RM; Brunsvig PF; Brustugun OT; Fløtten Ø; Levin N; Sundstrøm SH; Grønberg BH
    Anticancer Res; 2018 Feb; 38(2):871-876. PubMed ID: 29374714
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Survival and Prognostic Factors in Limited-stage Small-cell Lung Cancer.
    Atci MM; Sakin A; Uysal E; Aksaray F; Selvi O; Can O
    J Coll Physicians Surg Pak; 2021 Dec; 31(12):1433-1437. PubMed ID: 34794283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
    Thomas CR; Giroux DJ; Stelzer KJ; Craig JB; Laufman LR; Taylor SA; Goodwin JW; Crowley JJ; Livingston RB
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1039-47. PubMed ID: 9539558
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer.
    Fukuda M; Nakamura Y; Kinoshita A; Soejima Y; Yamaguchi H; Ikeda T; Izumikawa K; Takatani H; Fukuda M; Soda H; Hayashi N; Tsukamoto K; Oka M; Kohno S
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):645-51. PubMed ID: 23010852
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
    Kakolyris S; Agelidou A; Androulakis N; Tsaroucha E; Kouroussis Ch; Agelidou M; Karvounis N; Veslemes M; Christophylakis Ch; Argyraki A; Geroyianni A; Georgoulias V
    Lung Cancer; 2006 Jul; 53(1):59-65. PubMed ID: 16716447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer.
    Sekine I; Sumi M; Satouchi M; Tsujino K; Nishio M; Kozuka T; Niho S; Nihei K; Yamamoto N; Harada H; Ishikura S; Tamura T
    Cancer Sci; 2016 Mar; 107(3):315-9. PubMed ID: 26748638
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.
    Reboul F; Brewer Y; Vincent P; Chauvet B; Faure CF; Taulelle M
    Int J Radiat Oncol Biol Phys; 1996 May; 35(2):343-50. PubMed ID: 8635942
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcome and treatment in elderly patients with small cell lung cancer: a retrospective study.
    Li J; Chen P; Dai CH; Li XQ; Bao QL
    Geriatr Gerontol Int; 2009 Jun; 9(2):172-82. PubMed ID: 19740361
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
    Zatloukal P; Petruzelka L; Zemanova M; Havel L; Janku F; Judas L; Kubik A; Krepela E; Fiala P; Pecen L
    Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolic activity on [18f]-fluorodeoxyglucose-positron emission tomography/computed tomography and glucose transporter-1 expression might predict clinical outcomes in patients with limited disease small-cell lung cancer who receive concurrent chemoradiation.
    Lee J; Kim JO; Jung CK; Kim YS; Yoo IeR; Choi WH; Jeon EK; Hong SH; Chun SH; Kim SJ; Kim YK; Kang JH
    Clin Lung Cancer; 2014 Mar; 15(2):e13-21. PubMed ID: 24368212
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
    Barney CL; Scoville N; Allan E; Ayan A; DiCostanzo D; Haglund KE; Grecula J; Williams T; Xu-Welliver M; Otterson GA; Bazan JG
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):748-755. PubMed ID: 29413286
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer.
    Xia B; Hong LZ; Cai XW; Zhu ZF; Liu Q; Zhao KL; Fan M; Mao JF; Yang HJ; Wu KL; Fu XL
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):517-23. PubMed ID: 25481679
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Guideline for the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy.
    Sun A; Durocher-Allen LD; Ellis PM; Ung YC; Goffin JR; Ramchandar K; Darling G
    Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):658-666. PubMed ID: 30007803
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Duration of Twice-Daily Thoracic Radiotherapy and Time From the Start of Any Treatment to the End of Chest Irradiation as Significant Predictors of Outcomes in Limited-Disease Small-Cell Lung Cancer.
    Morimoto M; Okishio K; Akira M; Omachi N; Tamiya A; Asami K; Kawaguchi T; Atagi S
    Clin Lung Cancer; 2017 Mar; 18(2):e117-e127. PubMed ID: 28340925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel chemoradiotherapy with concomitant boost thoracic radiation and concurrent cisplatin and vinorelbine for stage IIIA and IIIB non-small-cell lung cancer.
    Imamura F; Konishi K; Uchida J; Nishino K; Okuyama T; Kumagai T; Kawaguchi Y; Nishiyama K
    Clin Lung Cancer; 2014 Jul; 15(4):281-6. PubMed ID: 24656641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.